Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Common Equity (2021 - 2025)

Bioregenx's Common Equity history spans 5 years, with the latest figure at -$4.5 million for Q4 2025.

  • Quarterly results put Common Equity at -$4.5 million for Q4 2025, down 34.27% from a year ago — trailing twelve months through Dec 2025 was -$4.5 million (down 34.27% YoY), and the annual figure for FY2025 was -$4.5 million, down 34.27%.
  • Common Equity for Q4 2025 was -$4.5 million at Bioregenx, down from -$3.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $15.1 million in Q1 2024 to a low of -$4.5 million in Q4 2025.
  • The 5-year median for Common Equity is -$2.4 million (2023), against an average of $652984.5.
  • The sharpest move saw Common Equity plummeted 2901.09% in 2022, then skyrocketed 724.59% in 2024.
  • Year by year, Common Equity stood at -$84234.0 in 2021, then plummeted by 2901.09% to -$2.5 million in 2022, then increased by 18.06% to -$2.1 million in 2023, then plummeted by 63.14% to -$3.4 million in 2024, then crashed by 34.27% to -$4.5 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at -$4.5 million, -$3.6 million, and -$3.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.